Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Ill. (PRWEB) , ... September ... ... leading provider of regulatory compliance, quality systems, analytical testing, education and consulting ... firm with expertise in medical device products/processes development, design control, validation, quality ...
(Date:9/2/2015)... Sep. 02, 2015 Research ... of Jain PharmaBiotech,s new report "Gene Therapy - ... The markets for gene therapy are difficult to ... product and it is marketed in China ... for the years 2014-2024. The estimates are based on ...
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Verenium Corporation,(Nasdaq: VRNM ), a leading ... the development of high-performance specialty enzymes, announced,today that ... present at,the upcoming Canaccord Adams 28th Annual Global ... 10:30 a.m. ET on Thursday, August 14,and will ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Monogram,Biosciences, Inc. ... Young, CEO,and Chairman, is scheduled to present an update ... Conference on Wednesday, September,3, 2008 at 11:30 a.m. (Eastern ... To access the live audio broadcast or the subsequent ...
... Medicsight PLC, a subsidiary,of MGT Capital Investments, Inc. ... in the,development of Computer-Aided Detection (CAD) and image ... from the Brazilian regulatory,agency, Agencia Nacional de Vigilancia ... Chief Executive of Medicsight, commented: "This is,another important ...
Cached Biology Technology:Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 2Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 3Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... 2013 Elsevier, a world-leading provider of scientific, ... announced that it received six 2012 PROSE Awards ... PROSE Awards the American Publishers Awards for ... the Association of American Publishers, Professional and Scholarly ...
... With biomedical scientists struggling to collect and analyze millions ... human health, the National Institutes of Health has launched ... framework and start training future scientists to tap that ... story in the current edition of Chemical & ...
... are needed to remove pollutants from water. RUB researchers ... seven different countries in order to develop a photocatalyst ... purpose, they combine sunlight-absorbing semiconductors and nanostructured materials which ... to implement the newly developed photocatalysts into a liquid ...
Cached Biology News:Elsevier wins 6 PROSE Awards 2Painting with catalysts: Nano-engineered materials for detoxifying water by use of sunlight 2
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
...
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
...
Biology Products: